PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 67 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,215 | +61.6% | 72,830 | +167.5% | 0.06% | +72.7% |
| Q2 2023 | $752 | +55.4% | 27,230 | +29.3% | 0.03% | +43.5% |
| Q1 2023 | $484 | -47.3% | 21,060 | -75.0% | 0.02% | -54.9% |
| Q4 2022 | $918 | -99.8% | 84,172 | +18.7% | 0.05% | +41.7% |
| Q3 2022 | $598,000 | -14.2% | 70,932 | -19.5% | 0.04% | -30.8% |
| Q2 2022 | $697,000 | +21.0% | 88,097 | +262.3% | 0.05% | +36.8% |
| Q1 2022 | $576,000 | +206.4% | 24,317 | +56.7% | 0.04% | -44.9% |
| Q2 2019 | $188,000 | +42.4% | 15,517 | +48.0% | 0.07% | -8.0% |
| Q1 2019 | $132,000 | +40.4% | 10,487 | -25.3% | 0.08% | +188.5% |
| Q4 2018 | $94,000 | -79.5% | 14,041 | -68.4% | 0.03% | -73.7% |
| Q3 2018 | $458,000 | +31.2% | 44,477 | -14.3% | 0.10% | +37.5% |
| Q2 2018 | $349,000 | – | 51,907 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $43,400,000 | 3.81% |
| BVF INC/IL | 3,901,759 | $69,139,000 | 2.70% |
| COMMODORE CAPITAL LP | 498,079 | $8,826,000 | 2.33% |
| Altium Capital Management LP | 346,000 | $6,131,000 | 1.61% |
| Twin Lakes Capital Management, LLC | 139,287 | $2,468,000 | 1.45% |
| Opaleye Management Inc. | 330,222 | $5,852,000 | 1.09% |
| EcoR1 Capital, LLC | 1,443,800 | $25,584,000 | 0.89% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 776,689 | $13,763,000 | 0.76% |
| JABODON PT CO | 90,656 | $1,606,000 | 0.66% |
| Artal Group S.A. | 1,500,000 | $26,580,000 | 0.60% |